SCHEMBL6766772

SCHEMBL6766772

Cc1c(Cl)ccc(S(=O)(=O)N(CCc2ccccc2)CC(=O)NCC(=O)N(CCCN)Cc2ccc(C(=N)N)cc2)c1Cl

nearest known ligand 0.81

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
BDKRB1 P46663 3/20 0.81
F10 P00742 2/20 0.39
CA12 O43570 5/20 0.38
CA1 P00915 5/20 0.38
CA2 P00918 5/20 0.38
CA4 P22748 4/20 0.38
LMNA P02545 2/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
ALDH1A1 P00352 2/20 0.37
TP53 P04637 1/20 0.36
LIMK2 P53671 1/20 0.36
F2 P00734 2/20 0.36
POLB P06746 1/20 0.35
MAPT P10636 1/20 0.35
HTT P42858 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
F7 P08709 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6762635 0.98 BDKRB1 (0.82) BDKRB1F10CA12CA1CA2
SCHEMBL6761589 0.94 BDKRB1 (0.80) BDKRB1F10CA12CA1CA2
SCHEMBL6762667 0.94 BDKRB1 (0.82) BDKRB1F10CA12CA1CA2
SCHEMBL6762734 0.94 BDKRB1 (0.80) BDKRB1F10LMNAMEN1KMT2A
SCHEMBL6761694 0.90 BDKRB1 (0.96) BDKRB1F10F2F7
SCHEMBL6761801 0.89 BDKRB1 (1.00) BDKRB1F10LMNAMEN1KMT2A
SCHEMBL6761665 0.89 BDKRB1 (0.72) BDKRB1F10LMNAMEN1KMT2A
SCHEMBL6760090 0.88 BDKRB1 (0.91) BDKRB1F10LMNAMEN1KMT2A
SCHEMBL6981011 0.88 BDKRB1 (0.78) BDKRB1CA12CA1CA2CA4
SCHEMBL6766780 0.88 BDKRB1 (0.64) BDKRB1CA12CA1CA2CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040063725-A1 Novel n(phenylsulphonyl)glycine derivatives and their therapeutic use LABORATORIES FOURNIER S.A. (FR) 2004-04-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063725-A1 Novel n(phenylsulphonyl)glycine derivatives and their therapeutic use GLS, GLS2, GLRB BDKRB1 481/4885F10 4430/4885CA12 3089/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.